Data Supplement
- Supplemental Data -
Supplemental Table 1 - NDAs approved by the U.S. FDA from 2013 to 2016
Supplemental Table 2 - Chemical structures of compounds within the NDAs approved in 2016 (ordered by approval date)
Supplemental Table 3 - Inhibition DDIs, NME as substrate
Supplemental Table 4 - Induction DDIs, NME as substrate
Supplemental Table 5 - Inhibition DDIs, NME as inhibitor
Supplemental Table 6 - Induction DDIs, NMEs as inducers
Supplemental Figure 1A - Therapeutic classes for inhibition DDIs with AUC ratios ≥ 5, NME as substrate (N = 14)
Supplemental Figure 2A - Therapeutic classes for induction DDIs with AUC ratios ≤ 0.2, NME as substrate (N = 14)
Supplemental Figure 3A - Therapeutic classes for inhibition DDIs with 2 ≤ AUC ratios < 5, NME as inhibitor (N = 11)